EGFR and non-small cell lung carcinoma: The prognosis of NSCLC is still poor, with the 5-year survival rate of 15%.1 In clinics, the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have been proven to be effective for the treatment of advanced NSCLC patients carrying sensitized EGFR mutations including the exon 19 deletion or the L858R mutation.2,3 Gefitinib is the firstly approved orally bioavailable, competitive, reversible EGFR-TKI for NSCLC with EGFR mutations.